+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
37.3000
1.0777
-.7747
37.3614
2.4510
5.6071
Low
82.2874
1.4859
Yes
No
No
No
No
No
0.0
Yes
No
Yes
Yes
Valeric acid (N-Valeric acid), also known as pentanoic acid, is a straight-chain saturated fatty acid containing five carbon atoms, with the chemical formula C5H10O2 and CAS number 109-52-4. As one of the common short-chain fatty acids in natural products, valoxalic acid plays an important role in plant metabolism and is widely found in various plants and their extracts. In recent years, with the rapid development of natural product pharmacology, valoxalic acid has attracted increasing attention due to its potential sedative and hypnotic effects. Its mechanism involves various neurotransmitter receptors and transport proteins, especially targets associated with 5-hydroxytryptamine receptors (HTR1A, HTR2A) and γ-aminobutyric acid receptors (GABRA1, GABRB2, GABRG2), indicating its importance in central nervous system regulation.
This review aims to systematically summarize the chemical structure and physicochemical properties of valoxalic acid, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and to explore its clinical application prospects and development potential in the field of sedation and hypnosis, providing theoretical basis and research directions for subsequent basic research and clinical translation.
Valoxalic acid has a molecular formula of C5H10O2 and a molecular weight of 102.1330. Its structure is a straight chain composed of five carbon atoms, with a carboxyl group (-COOH) at the end, making it a typical straight-chain saturated fatty acid. This structure imparts a certain hydrophobicity and hydrophilicity balance to valoxalic acid, with a LogP value of 1.0777, indicating moderate lipid solubility, which is beneficial for diffusion and penetration in biofilms.
Valoxalic acid has a polar surface area (TPSA) of 37.3 Ų and a water solubility of 37.3614 mg/mL, indicating good water solubility and facilitation of absorption and distribution in the body. Its low blood-brain barrier permeability suggests that valoxalic acid has limited direct entry into the central nervous system, but may act through indirect mechanisms or metabolites. Additionally, valoxalic acid does not exhibit hERG channel inhibitory activity, and Ames mutagenic test results are zero, indicating high safety and low toxicity risk.
Valoxalic acid, as a conjugate acid of valerate, has good chemical stability and easily exists in both acidic and neutral environments, making it suitable for the development of various drug formulations.
Valeriic acid is widely found in various plants, with Valeriana spp. being a representative example. Valerian roots and stems and leaves are rich in valeric acid and its derivatives, making it one of the important active ingredients in traditional herbal medicine. Besides valerian, other plants such as certain legumes and grasses also contain certain amounts of valeric acid.
There are various methods for extracting valoxalic acid, with commonly used methods including solvent extraction, distillation, and liquid-liquid extraction. Specific processes often use organic solvents such as ethanol, methanol, or ethyl acetate for extraction and then purification of high-purity valoxalic acid through vacuum concentration and column chromatography. In modern extraction technologies, ultrasound-assisted extraction and microwave-assisted extraction have gradually been applied to valine oxalic acid extraction due to their high efficiency and energy savings, effectively improving extraction rates and purity.
In addition, the synthetic routes for valoxalic acid are relatively mature and can be obtained in industrial production through chemical synthesis or microbial fermentation to meet the needs of large-scale production.
The pharmacological activity of valoxalic acid is mainly concentrated in the central nervous system, especially showing significant sedative and hypnotic effects. Early in vitro and in vivo experiments showed that valoxalic acid can regulate neurotransmitter release and receptor activity, improving symptoms of neuropsychiatric disorders such as anxiety and insomnia.
Valoxalic acid regulates the functions of serotonin receptors (5-HT1A, 5-HT2A) and GABA_A receptor subunits (GABRA1, GABRB2, GABRG2), enhances inhibitory nerve conduction, and exerts a sedative and hypnotic effect. In animal experiments, valoxalic acid significantly shortened sleep latency and extended sleep duration, exhibiting effects similar to benzodiazepines, but with milder side effects.
Some studies also show that valoxalic acid has anti-inflammatory and antioxidant effects, helping to reduce inflammatory responses and oxidative stress in the nervous system, thereby protecting neurons and preventing the occurrence and progression of neurodegenerative diseases.
As a short-chain fatty acid, valoxalic acid participates in energy and lipid metabolism regulation, influences the ecological balance of gut microbiota, and indirectly modulates central nervous system function, demonstrating the potential of "gut-brain axis" regulation.
The mechanism of action of valoxalic acid mainly relies on interactions with neurotransmitter receptors and transporters. Its main targets include:
The synergistic regulatory mechanisms of these targets make valoxalic acid a natural sedative hypnotizer with multi-target effects, offering good safety and tolerability.
Druggability evaluation of valoxalic acid indicates good drug development potential. Moderate molecular weight, reasonable LogP value, good water solubility, and favorable oral absorption. Although its blood-brain barrier permeability is low, it is expected to enhance the bioavailability of the central nervous system through metabolic conversion or adjunct drug delivery.
In terms of safety, valoxalic acid does not have significant hERG channel inhibitory effects, reducing the risk of cardiotoxicity; Ames test negative, indicating no mutagenicity. Pharmacokinetic studies show that valoxalic acid is widely distributed in the body, with metabolic pathways mainly through β-oxidation and esterification reactions, is rapidly excreted, and has a moderate half-life.
In the future, through structural modification and optimization of drug carrier technologies, it is expected that its pharmacokinetic properties will be further improved, enhancing efficacy and bioavailability.
Valoxalic acid, as a natural short-chain fatty acid, has broad clinical application prospects due to its remarkable sedative and hypnotic effects and good safety. Its potential in treating insomnia, anxiety, and related mental disorders is increasingly recognized, and it is especially suitable as an adjunct therapy for mild to moderate neuropsychiatric disorders.
Future research should focus on the following aspects:
Additionally, the potential of valoxalic acid in gut microecological regulation and neuroprotection is worth further exploration, potentially providing new ideas for the treatment of neurodegenerative and metabolic diseases.
In summary, valoxalic acid, as a natural short-chain fatty acid, has clear sedative and hypnotic pharmacological activity and good safety, involving regulation of various neurotransmitter receptors and transport proteins. Its physicochemical properties are suitable for drug development, and its abundant plant sources and mature extraction processes are available. In the future, through systematic pharmacological mechanism research and clinical validation, valoxalic acid is expected to become an important natural drug for treating neuropsychiatric diseases, promoting the development of natural product pharmacology and neuropharmacology.
With the deepening of interdisciplinary integration, research on valoxalic acid will provide a solid scientific foundation for developing new, safe, and efficient sedative hypnotic drugs, promoting the widespread application of natural products in modern medicine.
Shenshuai
Wenjing
Hedandan
